Galapagos nv

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. The joint venture operated until 2002 when the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels (Ticker symbol: GLPG) and Euronext Amsterdam (GLPGA) stock exchanges. In October 2005, Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK, through an all share offer, giving BioFocus shareholders a 29% state holding in the enlarged Company. On October 20, 2005 Galapagos started trading on the Alternative Investment Market of the London Stock exchange (Ticker symbol: GLPG). On June 13, 2006 Galapagos announced the acquisition of the drug discovery operations of Discovery Partners International, forming the new drug discovery division called BioFocus DPI.

Contact Details: Industriepark Mechelen Noord Generaal De Wittelaan L11 A3 Mechelen B-2800 Belgium Tel: 32 15 34 29 00 Fax: 32 15 34 29 01 Email: bd@glpg.com WWW: www.glpg.com/

Recent Publications by Galapagos nv:
The impact of parallel chemistry in drug discovery. With the application of parallel synthesis of single compounds to...	16th June, 2006	Department of Medicinal Chemistry, Galapagos NV, Industriepark Mechelen	IDrugs. 2006 May;9(5):347-53.

BioNews Results for Galapagos nv:
Galapagos Business Update	RBC Dain Rauscher:  Nov 13 2009 9:43AM Matching: galapagos nv
Galapagos third quarter 2009 financial results in line with management expectations	News-Medical.Net:  Nov 13 2009 12:32PM Matching: galapagos nv
Galapagos Business Update	Individual.com:  Nov 13 2009 7:11AM Matching: galapagos nv
Galapagos business update	Individual.com:  Nov 13 2009 7:11AM Matching: galapagos nv
Galapagos successfully completes placement of 2,125,925 new ordinary shares	PR-USA.net:  Oct 20 2009 6:38PM Matching: galapagos nv
Promote your company here: BioNewsCast - Press Release Distribution	→View more Galapagos nv news.

Galapagos nv Clinical Trials:
GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects

Galapagos nv Patents:
US Patent No.	Title
7501411	Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
7332337	Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 324 times since April 2007, the link to the organisation's website has been followed 62 times

Recent Search Terms used to find this page: galapagos nv mechelen | patents galapagos NV | Galapagos NV | galapagos nv | galapagos nv | galapagos mechelen | private placement galapagos | .

Search for more companies in Mechelen

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Galapagos nv